Deep Genomics, founded at University of Toronto and currently working with Wave Life Sciences out of Minnesota, will join forces to use artificial intelligence to identify treatments for genetic diseases using neuromuscular disorders – an illness category which includes Duchenne muscular dystrophy. Frey explained this work is ideal for his company’s machine learning technology.
Company Description
Deep Genomics is a biotechnology company that utilizes artificial intelligence (AI)-powered discovery platforms for the identification and prioritization of genetic medicines. They strive to streamline drug development processes using their AI technology; specifically splicing regulation which reveals cause-effect relationships of specific genes involved with neuromuscular disorders as an example. Wave’s proprietary chemistry platforms will be utilized alongside Deep Genomics AI technology in this partnership in order to identify new therapeutic targets while expanding druggable targets available against neuromuscular disorders.
Headquartered in Toronto
Wave Life Sciences and Deep Genomics are joining forces to find novel treatments for genetic neuromuscular disorders by applying Deep Genomics’ machine learning platform and Wave’s proprietary chemistry technology together to better understand splicing regulation, expand druggable targets and discover novel therapeutic approaches for neuromuscular diseases. Through their Artificial Intelligence capabilities and machine learning platform combined with Wave’s platform they hope to discover novel approaches targeting genes affecting neuromuscular disorders as well as rationally designed oligonucleotides to inhibit these targets.
Headquartered in Cambridge
Wave Life Sciences is harnessing RNA medicines to transform human health. Their revolutionary RNA editing oligonucleotide platform, PRISM, integrates multiple modalities and chemical innovations to design candidates that address disease biology efficiently and sustainably. Their first candidate RestorAATion-2 targets Achalasia Alanine Transpeptidase Deficiency by producing healthy wild-type M-AAT while decreasing unhealthy mutant Z-AAT aggregates found in liver and lung tissue.
Later this month, the company’s AATD program will be featured in a conference call and webcast, while preclinical data supporting WVE-008 development will be presented at EASL congress. Both programs use GalNAc-conjugated RNA editing technology that targets corrections directly within cells for improved patient health. Regulatory agencies should provide feedback by mid-2026 about potential expedited approval pathways for these products.
Deep Genomics and Wave have joined forces to collaborate in developing genetic medicines for neuromuscular disorders – such as Duchenne muscular dystrophy – which could provide much-needed treatments. The partnership allows Deep Genomics to expand their research efforts while giving Wave access to an expansive genomics discovery platform.
Wave Genetics may seem strange at first, but its technology has been demonstrated through several scientific experiments to work. According to its proponents, resonant waves can be directed toward DNA in ways similar to how Wright Brothers used their first airplane versus more modern gene editing technologies like CRISPR-Cas9.
Wave’s CEO Brendan Frey recently informed investors on an investor call that Wave intends to focus its research efforts on treatments for genetic neuromuscular diseases. According to him, this area of research combines well with their machine learning technology and is also growing sector where Wave holds an edge.
Wave also announced its intent to redomicile its parent company in Delaware, an action expected to streamline organizational and statutory structures of its organization and become effective mid-2026 subject to shareholder and Singapore High Court approvals. Once redomiciliation occurs, shares of this Delaware-domiciled parent will continue trading under its current trading symbol “WVE.”
Founded in 2015
The company has developed a proprietary method for predicting people’s risk for genetic diseases. Unlike traditional approaches, which rely on questionnaires or tests for symptoms, its approach looks at people’s genome to identify genes associated with susceptibility; then uses machine learning algorithms to predict those most likely to contract diseases and provide treatment plans to lower those risks.
This press release contains forward-looking statements, such as statements regarding Wave’s proprietary chemistry platform and Deep Genomics’ machine learning platform, as well as anticipated benefits that might result from their collaboration, such as deeper understanding of splicing biology, expanding druggable targets and increasing addressable patient populations. These statements reflect current beliefs and expectations but could differ materially in reality; risks and uncertainties associated with Wave’s drug development program, regulatory approval process and commercialization may all play a part.
